PSB-KD107

PSB-KD107 is a selective, non-lipid agonist of the orphan G protein-coupled receptor GPR18 (also known as the N-arachidonyl glycine receptor). Developed by the University of Bonn and Jagiellonian University, PSB-KD107 is a tricyclic xanthine derivative that exhibits high potency and efficacy at GPR18, with selectivity over cannabinoid receptors CB1 and CB2, as well as GPR55. It has been investigated as a research tool and therapeutic candidate for inflammatory conditions and muscle-wasting disorders, specifically demonstrating the ability to reduce inflammation, enhance myogenesis, and restore muscle function in preclinical models of Duchenne muscular dystrophy (DMD).

Other names

6,7,8,9-tetrahydro-9-[2-(1H-indol-3-yl)ethyl]-1,3-dimethyl-pyrimido[2,1-f]purine-2,4(1H,3H)-dione9-[2-(1H-indol-3-yl)ethyl]-1,3-dimethyl-7,8-dihydro-6H-purino[7,8-a]pyrimidine-2,4-dione